Keros Therapeutics, Inc. (KROS)
Automate Your Wheel Strategy on KROS
With Tiblio's Option Bot, you can configure your own wheel strategy including KROS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KROS
- Rev/Share 6.0733
- Book/Share 17.3196
- PB 0.9954
- Debt/Equity 0.0248
- CurrentRatio 29.8567
- ROIC 0.0548
- MktCap 698885688.0
- FreeCF/Share 2.1437
- PFCF 8.0255
- PE 10.8667
- Debt/Assets 0.0235
- DivYield 0
- ROE 0.0951
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KROS | Wells Fargo | -- | Overweight | -- | $26 | Oct. 20, 2025 |
| Downgrade | KROS | BofA Securities | Buy | Neutral | -- | $18 | June 10, 2025 |
| Downgrade | KROS | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Jan. 21, 2025 |
| Downgrade | KROS | Wedbush | Outperform | Neutral | -- | $15 | Jan. 17, 2025 |
| Reiterated | KROS | Oppenheimer | -- | Outperform | $102 | $63 | Dec. 16, 2024 |
| Downgrade | KROS | Guggenheim | Buy | Neutral | -- | -- | Dec. 16, 2024 |
| Reiterated | KROS | H.C. Wainwright | -- | Buy | $100 | $47 | Dec. 13, 2024 |
| Downgrade | KROS | TD Cowen | Buy | Hold | -- | -- | Dec. 12, 2024 |
| Downgrade | KROS | BTIG Research | Buy | Neutral | -- | -- | Dec. 12, 2024 |
| Downgrade | KROS | William Blair | Outperform | Market Perform | -- | -- | Dec. 12, 2024 |
News
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:
Read More
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ: KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Keros Therapeutics, Inc. (KROS)
- IPO Date 2020-04-08
- Website https://www.kerostx.com
- Industry Biotechnology
- CEO Jasbir S. Seehra
- Employees 163